
|Videos|March 21, 2022
The role of doublet and triplet therapies in prostate cancer
Author(s)Urology Times staff
“There are many studies now that have shown that these doublets and triplets seem to be better than just ADT alone,” says William K. Oh, MD.
Advertisement
In this video, William K. Oh, MD, discusses the rise of doublet and triplet therapies in the treatment of prostate cancer, and what questions are still being investigated related to these novel treatments.Oh is a clinical professor of medicine at the Icahn School of Medicine, Mount Sinai in New York, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
5










